Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and in peripheral and non-radiographic axial spondyloarthritis

David T Yu, MD
Section Editor
Joachim Sieper, MD
Deputy Editor
Paul L Romain, MD


The ability of anti-tumor necrosis factor (TNF)-alpha agents (TNF inhibitors) to reduce disease activity in patients with axial spondyloarthritis (SpA), including both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA), has been demonstrated in multiple randomized trials and several meta-analyses [1-3]. Similarly, several randomized trials have shown the efficacy of these agents in patients with peripheral SpA, including patients who have failed to respond to a traditional disease-modifying antirheumatic drug (DMARD) [4,5].

Other than recognized medical contraindications to anti-TNF therapy (eg, untreated latent tuberculosis, active infection, and moderate or severe heart failure), there are no convincing evidence-based indications to exclude any patients with AS from such treatment. However, the very high cost of these therapies is a major impediment to their more widespread use in symptomatic SpA [6]. To control healthcare costs, government agencies and health insurance payers have imposed restrictions on the use of these agents. These policies vary by payer. In some countries, such as the US, each health payer formulates its own rules regarding patient characteristics that are required to have the cost of anti-TNF therapy covered.

The Assessment of SpondyloArthritis International Society (ASAS) working group, an international organization of more than 100 experts from a variety of countries, first published a set of guidelines for use of anti-TNF agents in axial SpA in 2003, updated them in 2006 and 2010, and published a literature review in 2012 [7-11]. The guidelines address patient selection, monitoring, and discontinuation of these drugs in patients with AS and other axial SpA, including nr-axSpA. The ASAS guidelines represent an opinion of the majority of ASAS members. Although some questions have been raised in the context of these recommendations, they provide general guidelines that are helpful in making decisions regarding individual patients [12,13]. Most other guidelines (eg, from individual countries) use a similar approach to the ASAS guidelines. Many of the existing guidelines define practice for a particular region or for the patients covered by a particular payer. Thus, clinicians in each region need to consult the regulatory or insurance guidelines of their own country, region, insurer, or other payer to determine the criteria that patients must meet to have anti-TNF therapies approved by the responsible agency or insurer [14].

This topic reviews the ASAS guidelines for cost-conscious use of TNF inhibitors in patients with AS and nr-axSpA, and addresses additional related issues. Detailed reviews of the overall approaches to diagnosis and management of AS and other forms of SpA, including the use of TNF inhibitors as well as other agents, are presented separately. (See "Diagnosis and differential diagnosis of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults" and "Assessment and treatment of ankylosing spondylitis in adults" and "Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults".)


Patients who should receive anti-tumor necrosis factor (TNF) therapy should have the following:

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 08, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187.
  2. Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2015; 74:1241.
  3. Machado MA, Barbosa MM, Almeida AM, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 2013; 33:2199.
  4. Paramarta JE, De Rycke L, Heijda TF, et al. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis 2013; 72:1793.
  5. Mease P, Sieper J, Van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol 2015; 67:914.
  6. Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 2013; 19:621.
  7. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012; 51:1378.
  8. Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817.
  9. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65:316.
  10. van der Heijde D, Sieper J, Maksymowych WP, et al. Update of the ASAS recommendations on the use of TNF-blockers in ankylosing spondylitis. Arthritis Rheum 2009; 60:S670.
  11. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:905.
  12. Deodhar A, Reveille JD, van den Bosch F, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol 2014; 66:2649.
  13. Baraliakos X, Deodhar A. Unanswered questions in the management of axial spondyloarthritis: an opinion piece. Clin Rheumatol 2014; 33:1359.
  14. van den Berg R, Stanislawska-Biernat E, van der Heijde DM. Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide. Rheumatology (Oxford) 2011; 50:2270.
  15. Blachier M, Coutanceau B, Dougados M, et al. Does the site of magnetic resonance imaging abnormalities match the site of recent-onset inflammatory back pain? The DESIR cohort. Ann Rheum Dis 2013; 72:979.
  16. European Medicines Agency. Committee for medicinal products for human use. Summary of opinion (post authorisation). Humira (adalimumab). 21 June 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000481/WC500129074.pdf (Accessed on September 13, 2012).
  17. Vastesaeger N, Cruyssen BV, Mulero J, et al. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin 2014; 10:204.
  18. Assessment of SpondyloArthritis International Society. Ankylosing Spondylitis Disease Activity Score. http://www.asas-group.org/research.php?id=01#null (Accessed on October 15, 2013).
  19. Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 2011; 23:339.
  20. Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008; 58:88.
  21. Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol 2013; 31:S37.
  22. Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 2014; 28:807.
  23. Li EK, Griffith JF, Lee VW, et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 2008; 47:1358.
  24. Závada J, Uher M, Sisol K, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis 2016; 75:96.
  25. Miceli-Richard C, van der Heijde D, Dougados M. Spondyloarthropathy for practicing rheumatologists: diagnosis, indication for disease-controlling antirheumatic therapy, and evaluation of the response. Rheum Dis Clin North Am 2003; 29:449.
  26. Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12:R117.
  27. Haibel H, Sieper J. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker? Curr Opin Rheumatol 2010; 22:388.